{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:38:11Z","timestamp":1794616691257,"version":"4.9.1"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:p>Lecanemab reduces cerebral amyloid-\u03b2 burden in Alzheimer disease, but whether amyloid-related imaging abnormalities (ARIA) are associated with greater amyloid clearance remains unclear. We report 3 patients with comparable clinical backgrounds and similar baseline cognitive performance who underwent amyloid-\u03b2 PET before and after lecanemab treatment. Quantitative analysis using Centiloid showed a greater reduction in amyloid burden in the patient who developed ARIA than in the 2 patients without ARIA. These observations suggest ARIA may be associated with more pronounced treatment-related amyloid clearance, warranting further investigation in larger cohorts.<\/jats:p>","DOI":"10.1097\/rlu.0000000000006726","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T17:01:48Z","timestamp":1792774908000},"page":"1099-1101","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Amyloid PET Changes During Lecanemab Treatment in Patients With and Without Amyloid-related Imaging Abnormalities"],"prefix":"10.1097","volume":"51","author":[{"given":"Yaqin","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, First Hospital of Shanxi Medical University"},{"name":"Shanxi Key Laboratory of Molecular Imaging, Shanxi Medica University"},{"name":"Molecular Imaging Precision Medical Collaborative Innovation Center, Shanxi Medical University, Taiyuan, Shanxi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Ji","sequence":"additional","affiliation":[{"name":"Shanghai United Imaging Healthcare Co., Ltd., Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing United Imaging Healthcare Technology Development Co., Ltd., Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, First Hospital of Shanxi Medical University"},{"name":"Shanxi Key Laboratory of Molecular Imaging, Shanxi Medica University"},{"name":"Molecular Imaging Precision Medical Collaborative Innovation Center, Shanxi Medical University, Taiyuan, Shanxi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0376-982X","authenticated-orcid":false,"given":"Zhifang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, First Hospital of Shanxi Medical University"},{"name":"Shanxi Key Laboratory of Molecular Imaging, Shanxi Medica University"},{"name":"Molecular Imaging Precision Medical Collaborative Innovation Center, Shanxi Medical University, Taiyuan, Shanxi"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","article-title":"A single ascending dose study of bapineuzumab in patients with Alzheimer disease","volume":"24","author":"Black","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/jpm15090437","article-title":"Anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: evidence, ARIA risk, and precision patient selection","volume":"15","author":"Alkhalifa","year":"2025","journal-title":"J Pers Med"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/brain\/awh379","article-title":"A\u03b2-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy","volume":"128","author":"Scolding","year":"2005","journal-title":"Brain"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ana.10810","article-title":"Clinical manifestations of cerebral amyloid angiopathy-related inflammation","volume":"55","author":"Eng","year":"2004","journal-title":"Ann Neurol"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/jnnp-2025-337198","article-title":"Amyloid-related imaging abnormalities (ARIA) in Alzheimer\u2019s immunotherapy: a framework and challenges for global surveillance strategies","volume":"97","author":"Hu","year":"2026","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"e195137","DOI":"10.1172\/JCI195137","article-title":"Myeloid-mediated cerebral amyloid vasculitis and the potential role of the immune response in brain atrophy","volume":"135","author":"Castellani","year":"2025","journal-title":"J Clin Invest"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.jalz.2012.11.010","article-title":"Vascular alterations in PDAPP mice after anti-A\u03b2 immunotherapy: implications for amyloid-related imaging abnormalities","volume":"9","author":"Zago","year":"2013","journal-title":"Alzheimers Dement"},{"key":"R9-20261104","first-page":"e100276","article-title":"Amyloid positron emission tomography imaging at the onset of amyloid-related abnormalities with edema in an Alzheimer\u2019s disease patient","volume":"17","author":"Arai","year":"2025","journal-title":"Cureus"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:00:11Z","timestamp":1793826011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006726","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"2026-06-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}